Drug Type Small molecule drug |
Synonyms Draflazine (USAN/INN), 1399686, GSK-1399686 + [3] |
Target |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC30H33Cl2F2N5O2 |
InChIKeyIWMYIWLIESDFRZ-UHFFFAOYSA-N |
CAS Registry120770-34-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03906 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | BE | 15 Sep 2009 | |
Colitis, Ulcerative | Phase 2 | CA | 15 Sep 2009 | |
Colitis, Ulcerative | Phase 2 | DE | 15 Sep 2009 | |
Colitis, Ulcerative | Phase 2 | NO | 15 Sep 2009 | |
Colitis, Ulcerative | Phase 2 | SE | 15 Sep 2009 | |
Inflammatory Bowel Diseases | Phase 1 | GB | 25 Sep 2008 |
Phase 2 | 120 | placebo+asacol+GSK1399686 (Placebo) | snbiljvmgt(awlkwrogcu) = bsdsmengiq cfuqmawnhe (bebxtdwhbr, iftbezbqgu - tfblymqdkh) View more | - | 26 Jun 2017 | ||
(GSK1399686 10 mg) | snbiljvmgt(awlkwrogcu) = xprmwnrdwi cfuqmawnhe (bebxtdwhbr, zlcicvqsob - adytxvowdp) View more |